menu
    • menu

    Company profile for Restem

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RESTEM Group is a clinical-stage biotechnology company focused on pioneering adult stem cell therapies. With one Phase 2/3 and one Phase 1 clinical trial currently underway, and another Phase 2 trial set to begin, RESTEM has successfully completed three Phase 1 trials. Through its proprietary Restem-L platform, which utilizes Umbilical Lining Stem Cells (ULSC), RESTEM aims to develop best-in-class treatments for the underserve...
    RESTEM Group is a clinical-stage biotechnology company focused on pioneering adult stem cell therapies. With one Phase 2/3 and one Phase 1 clinical trial currently underway, and another Phase 2 trial set to begin, RESTEM has successfully completed three Phase 1 trials. Through its proprietary Restem-L platform, which utilizes Umbilical Lining Stem Cells (ULSC), RESTEM aims to develop best-in-class treatments for the underserved autoimmune community.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RestemUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1728 Coral Way Suite 500 Miami, FL 33145
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.restem.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RESTEM Reveals Corporate Update And 2026 Strategic Focus
    RESTEM Reveals Corporate Update And 2026 Strategic Focus

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215317/0/en/RESTEM-Provides-Corporate-Update-and-Announces-Strategic-Priorities-for-2026.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    RESTEM To Join 15Th Lifesci Partners Event At J.P. Morgan Conf
    RESTEM To Join 15Th Lifesci Partners Event At J.P. Morgan Conf

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207667/0/en/RESTEM-to-Participate-in-the-15th-LifeSci-Partners-Corporate-Access-Event-Held-During-the-J-P-Morgan-Healthcare-Conference-in-January-2026.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Restem Doses First FSHD Patient in Phase 1/2a Restem-L Study
    Restem Doses First FSHD Patient in Phase 1/2a Restem-L Study

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201454/0/en/RESTEM-Announces-First-Patient-Dosed-in-the-Phase-1-2a-Study-of-Restem-L-in-Facioscapulohumeral-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Restem to Host R&D Day Showcasing Next-Gen Immunomodulatory
    Restem to Host R&D Day Showcasing Next-Gen Immunomodulatory

    11 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/11/3148766/0/en/RESTEM-to-Host-R-D-Day-Highlighting-its-Next-Generation-Immunomodulatory-Treatment-for-Autoimmune-and-Inflammatory-Diseases.html

    GLOBENEWSWIRE
    11 Sep 2025
    Share Share
    Restem to Present IIMPACT Trial Design at EULAR 2025 Congress
    Restem to Present IIMPACT Trial Design at EULAR 2025 Congress

    06 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/06/3095442/0/en/RESTEM-to-Present-Phase-2-3-IIMPACT-Trial-Design-in-Idiopathic-Inflammatory-Myopathy-at-EULAR-2025-Congress.html

    GLOBENEWSWIRE
    06 Jun 2025
    Share Share
    Restem to Present at the 2025 BIO International Convention
    Restem to Present at the 2025 BIO International Convention

    03 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/03/3093055/0/en/RESTEM-to-Present-at-the-2025-BIO-International-Convention.html

    GLOBENEWSWIRE
    03 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search